Covid19-Sources

4433 bookmarks
Custom sorting
Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors
Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors
The SARS-CoV-2 infection determines the COVID-19 syndrome characterized, in the worst cases, by severe respiratory distress, pulmonary and cardiac fibrosis, inflammatory cytokine release, and immunosuppression. This condition has led to the death of about ...
·ncbi.nlm.nih.gov·
Evidence for Biological Age Acceleration and Telomere Shortening in COVID-19 Survivors
Long covid sufferers struggling with work
Long covid sufferers struggling with work
Three in four (78%) Long COVID sufferers have had to stop, pause, reduce or change their work since experiencing symptoms, according to a new report. With approximately 2.1 million people (3.5% of the population) currently living with Long COVID in the UK and workforce inactivity due to long-term sickness at an all-time high, the study reveals Long COVID’s significant impact on the workforce.
·smeweb.com·
Long covid sufferers struggling with work
Has covid-19 become milder?
Has covid-19 become milder?
Deaths and hospital admissions are falling, so does this mean that the virus is less severe? The BMJ asks the experts The short answer is no. Covid-19 is still a deadly disease, having killed almost 1.1 million people in 2022 at the time of writing. There remains a high risk of hospital admission and death for anyone without prior immunity. With some populations still largely unexposed to the virus, such as in China, and variation in the types of vaccines used in different places, it would be cavalier to call covid-19 anything but serious. “It’s really hard to compare the severe disease aspects of [variants] because the immunity of our population is so different,” says Steve Griffin, associate professor at the University of Leeds. “When people call omicron mild, yes, there’s probably a lesser tendency for it to go deep in the lungs. But if you think about the clinical impact of it, because of its massive prevalence, even though it’s got a lower chance of causing the sorts of severe disease we’re talking about with acute covid-19, the actual clinical impact is still very, very marked.” David Strain, senior clinical lecturer at the University of Exeter Medical School, points out that covid-19 tends to make other diseases worse. “It doesn’t matter what those other diseases are,” he told The BMJ in August 2022. “Patients who’ve …
·bmj.com·
Has covid-19 become milder?
Ralf Wittenbrink on Twitter
Ralf Wittenbrink on Twitter
Was genau kann #COVID19 im menschlichen Gehirn anrichten?In einer neuen Studie, die in der Zeitschrift Molecular Psychiatry veröffentlicht wurde, versuchten Forscher aus Schweden und einem Harvard-Krankenhaus in Boston, dies herauszufinden, indem sie…#LongCovid #Corona pic.twitter.com/CIgK3NQbsY— Ralf Wittenbrink (@RWittenbrink) November 7, 2022
·twitter.com·
Ralf Wittenbrink on Twitter
Dr Claire Taylor on Twitter
Dr Claire Taylor on Twitter
Clinical pearls for #LongCovid 1. Find the clots. They are there. If not PE or DVT there are Microclots. 100% of all long Covid patients tested so far have them.— Dr Claire Taylor (@drclairetaylor) November 6, 2022
·twitter.com·
Dr Claire Taylor on Twitter
Ralf Wittenbrink on Twitter
Ralf Wittenbrink on Twitter
Ein weiteres Beispiel dafür, dass Viruserkrankungen in der Kindheit das Immunsystem nicht stärken, sondern schwächen können ist das Respiratorische Synzytialvirus (RSV). RSV ist eine häufige Ursache für akute…#COVID19 #ImpfenSchuetzt #LongCovidKids #ProtectTheKids #Corona pic.twitter.com/OQgi9KlbRV— Ralf Wittenbrink (@RWittenbrink) November 5, 2022
·twitter.com·
Ralf Wittenbrink on Twitter
OrthopaeDenker on Twitter
OrthopaeDenker on Twitter
‼️Impfung inclu. 2 Booster reduziert das Covid19 Sterbe-Risiko in der Altersgruppe 50+ um 91% zeigen Daten des @CDCgov !Unsere2.- Boosterquote ist Kathastrophal.Aber was können wir noch tun um zu motivieren??#Boostershot #Booster https://t.co/7dudIwWR7y— OrthopaeDenker (@dokhollidays) October 22, 2022
·twitter.com·
OrthopaeDenker on Twitter
Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis
Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis
Background The impact of COVID-19 vaccination on preventing or treating long COVID is unclear. We aim to assess the impact of COVID vaccinations administered (i) before and (ii) after acute COVID-19, including vaccination after long COVID diagnosis, on the rates or symptoms of long COVID. Methods We searched PubMed, Embase, Cochrane COVID-19 trials, and Europe PMC for preprints from 1 Jan 2020 to 16 Feb 2022. We included trials, cohort, and case control studies reporting on long COVID cases and symptoms with vaccine administration both before and after COVID-19 diagnosis as well as after long COVID diagnosis. Risk of bias was assessed using ROBINS-I. Results We screened 356 articles and found no trials, but 6 observational studies from 3 countries (USA, UK, France) that reported on 442,601 patients. The most common long COVID symptoms studied include fatigue, cough, loss of smell, shortness of breath, loss of taste, headache, muscle ache, trouble sleeping, difficulty concentrating, worry or anxiety, and memory loss or confusion. Four studies reported data on vaccination before SARS-CoV-2 infection, of which three showed statistically significant reduction in long COVID: the odds ratio of developing long COVID with one dose of vaccine ranged between OR 0.22 to 1.03; with two doses OR 0.51 to 1; and with any dose OR 0.85 to 1.01. Three studies reported on post-infection vaccination with odds ratios between 0.38 to 0.91. The high heterogeneity between studies precluded any meaningful meta-analysis. Studies failed to adjust for potential confounders such as other protective behaviours, and missing data, thus increasing the risk of bias, and decreasing the certainty of evidence to low. Discussion Current studies suggest that COVID-19 vaccinations may have protective and therapeutic effects on long COVID. However, more robust comparative observational studies and trials are urgently needed to clearly determine effectiveness of vaccines in prevention and treatment of long COVID. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement OB is supported by NHMRC Grant APP1106452. PG is supported by NHMRC Australian Fellowship grant 1080042. There was no funding source for this study. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present work are contained in the manuscript
·medrxiv.org·
Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis
Eric Topol auf Twitter
Eric Topol auf Twitter
“Since Omicron in late 2021, mRNA booster protection vs infections & transmission declined substantially. But there are still major positive, data-driven (see prior posts for links) attributes for their net benefit for now. I've tried to summarize the + and - in a brief table.”
·twitter.com·
Eric Topol auf Twitter
COVID-19 mouth care guidance
COVID-19 mouth care guidance
We advise that patients who have COVID-19, or who are suspected of having COVID-19, should follow careful steps to ensure good mouth care during and after their illness. This advice is based on: 1) research demonstrating that the mouth is a reservoir of SARS-CoV-2 (the virus that causes COVID-19) and is a site of virus copying; and 2) research which suggests that the virus could pass from saliva into the blood vessels of the mouth and then travel to the lungs via the bloodstream, rather than just by inhalation into the airways of the lungs.
·patientinfo.microguide.global·
COVID-19 mouth care guidance
Eric Feigl-Ding on Twitter
Eric Feigl-Ding on Twitter
NOT BENIGN—"It's messing with our brains”—#COVID increases ⬆️risk of 44 neurological disorders, including Alzheimer's, 1 year post-infection—says @zalaly, as well as tremors, strokes, encephalitis & more. #LongCovid is real. @hereandnowrobin @hereandnow https://t.co/qFuoxGhZSW pic.twitter.com/Xk9Kx305G0— Eric Feigl-Ding (@DrEricDing) October 10, 2022
·twitter.com·
Eric Feigl-Ding on Twitter
SARS-CoV-2 vaccine and increased myocarditis mortality risk:
SARS-CoV-2 vaccine and increased myocarditis mortality risk:
Myocarditis mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) after10 receiving SARS-CoV-2 vaccine compared with that in the reference population (previous 3 years)11 were significantly higher not only in young adults (highest in the 30s with MMRR of 6.69) but also12 in the elderly. Standardised mortality ratio (SMR) for myocarditis was 1.65 (1.07 to 2.55) for those13 60 years or older and 2.01 (1.44 to 2.80) in overall age. The risk of myocarditis mortality in the14 SARS-CoV-2 vaccinated population may be 4 times or higher than the apparent MMRRs15 considering healthy vaccinee effect. Unreported post-vaccination deaths should also be considered16 as suggested by the extremely high myocarditis mortality odds ratio (205.60; 133.52 to 311.94)
·medrxiv.org·
SARS-CoV-2 vaccine and increased myocarditis mortality risk:
Jan Hartmann on Twitter
Jan Hartmann on Twitter
1/ 🧵Zweite Studie zu BA.5-Impfstoffen. Zunächst zu Ergebnissen, dann allg. Einordnung. Es wurden Ak-Titer bei 15/18 Pers. nach WT- und BA.5/WT-Booster verglichen. Nach BA.5/WT Titer gg. BA.5 1.3x höher 3 Wochen post-Vacc.als nach WT. Das entspricht➡️https://t.co/LHnogyJRxY pic.twitter.com/4hu6Ep52Xs— Jan Hartmann (@pelagicbird) October 26, 2022
·twitter.com·
Jan Hartmann on Twitter
Eric Feigl-Ding on Twitter
Eric Feigl-Ding on Twitter
⚠️BREAKING—CDC now confirms my scoop that super evasive #BQ1 & #BQ11 variants (Typhon & Cerberus) have meteorically surged from *unlisted* 3 weeks ago, to 11% 2 weeks ago—to ⬆️now suddenly 27% today! This is a bad 10-day doubling time! 🇬🇧’s #BQ ~30% too🧵https://t.co/amAjDWufhr pic.twitter.com/TGBFPAgpFJ— Eric Feigl-Ding (@DrEricDing) October 28, 2022
·twitter.com·
Eric Feigl-Ding on Twitter
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
The SARS-CoV-2 pandemic has highlighted the need for vaccines that not only prevent disease, but also prevent transmission. Parenteral vaccines induce robust systemic immunity, but poor immunity at the respiratory mucosa. Here we describe the development of a vaccine strategy we term “prime and spike” that leverages existing immunity generated by primary vaccination (prime) to elicit mucosal immune memory within the respiratory tract using unadjuvanted intranasal spike boosters (spike). We show that prime and spike induces robust resident memory B and T cell responses, IgA at the respiratory mucosa, boosts systemic immunity, and completely protects mice with partial immunity from lethal SARS-CoV-2 infection. Using divergent spike proteins, prime and spike enables induction of cross-reactive immunity against sarbecoviruses.
·science.org·
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Operation Nasal Vaccine—Lightning speed to counter COVID-19
Operation Nasal Vaccine—Lightning speed to counter COVID-19
Just 10 months after the initial genome sequencing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, two mRNA vaccines were demonstrated to provide 95% efficacy against symptomatic infections via randomized, placebo-controlled trials of more than 74,000 participants (1). That unprecedented success was, in part, fueled by the $10 billion governmental investment in Operation Warp Speed (OWS) in March 2020 to accelerate the development, manufacturing, and distribution of coronavirus disease 2019 (COVID-19) vaccines. We urgently need such an accelerated initiative now for nasal vaccines. During the first year of the pandemic, meaningful evolution of the virus was slow-paced, without any functional consequences, but since that time, we have seen a succession of important variants of concern with increasing transmissibility and immune evasion, culminating in the Omicron lineages. With that, there has been a marked falloff in the capacity for vaccinations and booster shots to block infections and transmission (2). A major unmet clinical need has arisen to block the transmission chain, prevent the frequent breakthrough infections, and achieve high levels of durable protection against severe disease, no less prevent post-acute sequelae of SARS-CoV-2 infection (PASC, or long COVID).
·science.org·
Operation Nasal Vaccine—Lightning speed to counter COVID-19
p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics)
p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics)
SARS-CoV-2 infection affects different organs and tissues, including the upper and lower airways, the lung, the gut, the olfactory system and the eye, which may represent one of the gates to the central nervous system. Key transcriptional factors, such as p53 and NF-kB and their reciprocal balance, are altered upon SARS-CoV-2 infection, as well as other key molecules such as the virus host cell entry mediator ACE2, member of the RAS-pathway. These changes are thought to play a central role in the impaired immune response, as well as in the massive cytokine release, the so-called cytokine storm that represents a hallmark of the most severe form of SARS-CoV-2 infection. Host genetics susceptibility is an additional key side to consider in a complex disease as COVID-19 characterized by such a wide range of clinical phenotypes. In this review, we underline some molecular mechanisms by which SARS-CoV-2 modulates p53 and NF-kB expression and activity in order to maximize viral replication into the host cells. We also face the RAS-pathway unbalance triggered by virus-ACE2 interaction to discuss potential pharmacological and pharmacogenomics approaches aimed at restoring p53/NF-kB and ACE1/ACE2 balance to counteract the most severe forms of SARS-CoV-2 infection.
·frontiersin.org·
p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics)
Ralf Wittenbrink on Twitter
Ralf Wittenbrink on Twitter
„Die Pandemie ist noch nicht vorbei“Globale Mortalitätstrends deuten auf eine anhaltend hohe Übersterblichkeit in den letzten 12 Monaten hin und legen nahe, dass die Pandemie noch nicht vorbei ist. In den vergangenen 12 Monaten lag die globale Übersterblichkeit 🧵#COVID19 pic.twitter.com/DuUoeg2jJH— Ralf Wittenbrink (@RWittenbrink) October 28, 2022
·twitter.com·
Ralf Wittenbrink on Twitter
Martin Moder on Twitter
Martin Moder on Twitter
Schützt der angepasste #Booster (BA.4/5) besser vor den neuen Varianten als der ursprüngliche? Zwei Arbeiten lassen vermuten, dass dem nicht so ist. Gestern und vorgestern als Pre-Print erschienen. Aber ganz so einfach ist es nicht. Schau ma uns die Burschen mal an. 1/11— Martin Moder (@Martin_Moder) October 26, 2022
·twitter.com·
Martin Moder on Twitter
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters. ### Competing Interest Statement The authors have declared no competing interest.
·biorxiv.org·
Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters